NVision Imaging closes $55M Series B with $17M EIB venture loan; expands from quantum-sensing POLARIS MRI platform into a new PIQC quantum-computing product line
On 2026-05-13 NVision Imaging Technologies GmbH (Ulm, Germany) announced the close of a $55M Series B equity financing accompanied by a separate $17M venture loan from the European Investment Bank (EIB), bringing cumulative capital raised since founding to approximately $120M. Abbott (NYSE: ABT) is the round's sole strategic-investor lead. Additional named participants: CDP Venture Capital (Italian state-backed VC under Cassa Depositi e Prestiti), Playground Global, Matterwave Ventures (Munich-based deep-tech VC, an NVision investor since 2017), b2venture (Swiss deep-tech VC), and Entrée Capital (London-based multi-stage VC). NVision's commercial product today is POLARIS, a hyperpolarised-MRI signal-amplification platform that uses parahydrogen-driven polarisation transfer to boost MRI signal by up to ~100,000x and enables cellular-level metabolic imaging on standard MRI scanners. POLARIS is currently installed at Memorial Sloan Kettering Cancer Center, the University of Cambridge, and the Technical University of Munich, with approximately twenty further installations planned across the US, Europe, and Asia by end-2026. Concurrent with the round, NVision announced expansion from quantum sensing into quantum computing via a new product line, Photonic Integrated Quantum Circuits (PIQC, pronounced 'Pixie'), which integrates organic-molecule-based qubits as thin layers onto photonic chips fabricated with standard semiconductor processes. PIQC is positioned within NVision's drug-design 'compute-and-validate' workflow, paired with the POLARIS imaging platform for closed-loop discovery and validation of therapeutic candidates. No PIQC benchmark numbers (qubit count, coherence time, gate fidelity, named-metric performance) were disclosed at announcement.
Score 6 — anchor §8.2 row 6 'A $50-150M Series B for a software/middleware or sensing/networking company' applied at the lower edge ($55M equity, $72M including the EIB venture-loan tranche), with NVision as a credible quantum-sensing name with named commercial deployment (MSK, Cambridge, TUM) and a named strategic-investor lead (Abbott). Held at 6 rather than 7 because (a) the $55M equity is at the low end of the band and below the $150-500M Series B/C hardware-anchor (row 8) threshold for a 7 or 8; (b) the announced PIQC quantum-computing expansion is at a development-stage product with no disclosed qubit count, coherence, fidelity, or named-metric benchmark; (c) PIQC is a strategic pivot rather than a separate financing or named external customer commitment. Cross-comparison: the trailing-30-day hardware financing cluster (QuantWare $178M Series B 2026-05-05 scored 8, eleQtron €57M Series A 2026-05-05 scored 7, Quantum Motion $160M Series C 2026-05-07 scored 7, Photonic Inc. $200M USD final close 2026-05-12 scored 7) frames NVision $55M Series B as the smallest in the cluster and the only sensing-anchored round; score 6 places it one band below the trailing comparables. Source confidence high (NVision corporate press release, EQS-News distribution, HPCwire and The Quantum Insider trade-press confirmation). Interpretation confidence medium (PIQC product specs, EIB venture-loan tranche structure beyond the $17M headline, and the cumulative-capital $120M reconciliation against prior fundraising rounds are not separately broken out in the announcement).
Extends the trailing-30-day European-deep-tech quantum capital cluster: QuantWare $178M Series B (2026-05-05, NL, superconducting), eleQtron €57M Series A (2026-05-05, DE, trapped-ion), Quantum Motion $160M Series C (2026-05-07, UK, silicon-spin), Photonic Inc. $200M USD final close (2026-05-12, CA, silicon T-centre), and now NVision Imaging $55M Series B (2026-05-13, DE, hyperpolarised-MRI sensing + PIQC photonic-computing pivot). Cumulative announced trailing-30-day capital across the five rounds now exceeds $650M USD-equivalent across five distinct modalities/sub-domains. Watch for: (a) NVision's first PIQC technical disclosure with a named-metric benchmark — none provided at announcement; (b) Abbott's commercial engagement scope beyond strategic-investor status (whether the POLARIS hyperpolarised-MRI platform converts into a named Abbott diagnostic-agent partnership or a PIQC drug-discovery commercial contract); (c) the EIB's appearance in the quantum-investor universe — first venture-loan participation in a European deep-tech quantum financing observed by the system; whether this signals a pattern of EIB participation in subsequent quantum financings parallels the BDC/EDC Canadian Crown-corporation participation pattern observed at the 2026-05-12 Photonic Inc. close; (d) the trajectory of POLARIS clinical installations toward the announced ~20 centers by end-2026 — a deployable count is one of the few directly-verifiable commercial-validation signals in quantum sensing; (e) NVision's PIQC qubit-count and fidelity progress against the announced 'standard semiconductor manufacturing' fabrication claim, which would, if verified, place it adjacent to the silicon-photonic foundry-process arc shared with PsiQuantum (GlobalFoundries) and Quantum Motion (GlobalFoundries).